Adicet Bio's Q2 Net Loss Widens
7:40AM ET 8/10/2022 MT NewswiresAdicet Bio (ACET) reported Q2 net loss Wednesday of $0.56 per diluted share, widening from a loss of $0.34 a year earlier. Analysts polled by Capital IQ...
Adicet Bio (ACET) reported Q2 net loss Wednesday of $0.56 per diluted share, widening from a loss of $0.34 a year earlier. Analysts polled by Capital IQ...
Blake Aftab, Chief Scientific Officer, on August 01, 2022, sold 6,968 shares in Adicet Bio (ACET) for $115,948. Following the Form 4 filing with the SEC,...
Adicet Bio (ACET) said Tuesday the US Food and Drug Administration has granted fast track designation to ADI-001, a CD20-targeted experimental medicine for...
Adicet Bio (ACET) has an average rating of buy and price targets ranging from $21 to $35, according to analysts polled by Capital IQ. (MT Newswires covers...
Address | 200 Berkeley Street Boston, Massachusetts 02116 |
Phone | +1.650.503.9095 |
Number of Employees | N/A |
Recent SEC Filing | 08/11/2022![]() |
President, CEO, Secretary & Director | Chen Schor |
Chief Financial Officer | Brian Nicholas Harvey |
Chief Medical Officer & Senior Vice President | Francesco Galimi |
Chief Technology Officer | Donald Healey |
Price Open | $14.38 |
Previous Close | $14.69 |
52 Week Range | $6.25 - 21.17 |
Market Capitalization | $572.4 M |
Shares Outstanding | 40.0 M |
Sector | Health Technology |
Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/09/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | N/A |
Earnings per Share | -$1.37 |
Beta vs. S&P 500 | N/A |
Revenue | $0.00 |
Net Profit Margin | -140.90% |
Return on Equity | -16.98% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |